Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$18.30 +0.9%	$20.24	$10.21 ▼ $25.67	$4.36B	0.43	3.71 million shs	1.05 million shs
BCLI Brainstorm Cell Therapeutics	$1.14 -2.6%	$1.17	$0.72 ▼ $6.45	$11.41M	0.22	389,647 shs	98,008 shs
CASI CASI Pharmaceuticals	$1.33 0.0%	$1.71	$1.09 ▼ $7.67	$15.99M	0.53	50,810 shs	12,568 shs
LJPC La Jolla Pharmaceutical		$5.73	$3.07 ▼ $6.24	$155.11M	2.39	158,476 shs	66,708 shs
LOGC LogicBio Therapeutics	$7.30 +0.7%	$2.06	$0.26 ▼ $3.77	$191.84M	2.06	168,718 shs	73,796 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	0.00%	+0.74%	-8.25%	+1.58%	+63.20%
BCLI Brainstorm Cell Therapeutics	0.00%	+7.55%	+0.88%	-0.88%	-77.80%
CASI CASI Pharmaceuticals	0.00%	+10.83%	-28.88%	-36.36%	-74.67%
LJPC La Jolla Pharmaceutical	0.00%	0.00%	0.00%	0.00%	0.00%
LOGC LogicBio Therapeutics	0.00%	+9.77%	+9.28%	+5.95%	+26.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMA ADMA Biologics	4.2235 of 5 stars	3.7	2.0	0.0	0.0	3.4	2.5	3.1
BCLI Brainstorm Cell Therapeutics	4.1085 of 5 stars	3.5	4.0	0.0	4.7	0.6	0.8	0.6
CASI CASI Pharmaceuticals	4.1211 of 5 stars	3.5	5.0	0.0	4.3	0.6	1.7	0.0
LJPC La Jolla Pharmaceutical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LOGC LogicBio Therapeutics	1.4441 of 5 stars	0.0	4.0	0.0	4.7	0.6	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	3.33	Buy	$27.67	51.23% Upside
BCLI Brainstorm Cell Therapeutics	3.00	Buy	$30.00	2,531.58% Upside
CASI CASI Pharmaceuticals	3.00	Buy	$4.00	200.75% Upside
LJPC La Jolla Pharmaceutical	0.00	N/A	N/A	N/A
LOGC LogicBio Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest LOGC, CASI, ADMA, BCLI, and LJPC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/19/2025	CASI CASI Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
5/8/2025	ADMA ADMA Biologics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$25.00 ➝ $32.00
4/9/2025	CASI CASI Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $4.00

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$426.45M	10.24	$0.54 per share	33.77	$1.48 per share	12.36
BCLI Brainstorm Cell Therapeutics	N/A	N/A	N/A	N/A	($1.36) per share	N/A
CASI CASI Pharmaceuticals	$28.54M	0.57	N/A	N/A	$0.12 per share	11.08
LJPC La Jolla Pharmaceutical	$75.72M	0.00	N/A	7.95	($2.94) per share	0.00
LOGC LogicBio Therapeutics	$287M	0.67	N/A	N/A	$8.96 per share	0.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$197.67M	$0.85	21.52	26.51	N/A	45.01%	47.16%	30.51%	8/6/2025 (Estimated)
BCLI Brainstorm Cell Therapeutics	-$11.62M	-$3.36	N/A	N/A	N/A	N/A	N/A	-519.50%	8/13/2025 (Estimated)
CASI CASI Pharmaceuticals	-$39.26M	-$2.55	N/A	∞	N/A	-129.05%	-972.55%	-77.33%	8/15/2025 (Estimated)
LJPC La Jolla Pharmaceutical	$19.66M	$0.12	51.84	0.00	N/A	8.54%	-5.46%	4.00%	N/A
LOGC LogicBio Therapeutics	-$317M	-$5.79	N/A	∞	N/A	-141.03%	-81.98%	-52.13%	N/A

Latest LOGC, CASI, ADMA, BCLI, and LJPC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/16/2025	Q1 2025	CASI CASI Pharmaceuticals	-$0.61	-$0.69	-$0.08	-$0.69	$7.39 million	$6.24 million
5/15/2025	Q1 2025	BCLI Brainstorm Cell Therapeutics	-$0.38	-$0.45	-$0.07	-$0.45	N/A	N/A
5/9/2025	Q1 2025	LOGC LogicBio Therapeutics	N/A	-$0.27	N/A	-$0.27	N/A	N/A
5/7/2025	Q1 2025	ADMA ADMA Biologics	$0.16	$0.14	-$0.02	$0.11	$116.40 million	$114.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
BCLI Brainstorm Cell Therapeutics	N/A	N/A	N/A	N/A	N/A
CASI CASI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LJPC La Jolla Pharmaceutical	N/A	N/A	N/A	N/A	N/A
LOGC LogicBio Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.22	6.58	3.36
BCLI Brainstorm Cell Therapeutics	N/A	0.21	0.21
CASI CASI Pharmaceuticals	N/A	0.81	0.68
LJPC La Jolla Pharmaceutical	N/A	4.02	3.52
LOGC LogicBio Therapeutics	N/A	31.60	31.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
BCLI Brainstorm Cell Therapeutics	14.33%
CASI CASI Pharmaceuticals	22.23%
LJPC La Jolla Pharmaceutical	97.06%
LOGC LogicBio Therapeutics	46.05%

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.50%
BCLI Brainstorm Cell Therapeutics	11.15%
CASI CASI Pharmaceuticals	21.24%
LJPC La Jolla Pharmaceutical	36.30%
LOGC LogicBio Therapeutics	8.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	530	238.73 million	230.38 million	Optionable
BCLI Brainstorm Cell Therapeutics	40	9.84 million	8.74 million	Optionable
CASI CASI Pharmaceuticals	180	12.30 million	9.69 million	Optionable
LJPC La Jolla Pharmaceutical	61	24.94 million	15.89 million	Optionable
LOGC LogicBio Therapeutics	62	26.28 million	24.16 million	Optionable

LOGC, CASI, ADMA, BCLI, and LJPC Headlines

Recent News About These Companies

ContextLogic Appoints Finance Executive Michael Scarola as New Chief Financial Officer

June 25, 2025 | globenewswire.com

ContextLogic Stock Price, Quotes and Forecasts | NASDAQ:LOGC | Benzinga

June 2, 2025 | benzinga.com

ContextLogic Inc. to Commence Trading on the OTC Markets and Delist from Nasdaq

May 30, 2025 | globenewswire.com

ContextLogic Inc. (LOGC) Q1 2025 Earnings Call Transcript

May 9, 2025 | seekingalpha.com

ContextLogic Inc. Reports First-Quarter 2025 Financial Results

May 9, 2025 | globenewswire.com

ContextLogic to Announce First Quarter 2025 Results on May 9, 2025

May 6, 2025 | globenewswire.com

ContextLogic Inc. Reports Fourth-Quarter and Fiscal Year 2024 Financial Results

March 12, 2025 | globenewswire.com

ContextLogic to Announce Fourth Quarter and Full Year 2024 Results and Provide Strategic Update on March 12, 2025

March 10, 2025 | globenewswire.com

LOGC stock touches 52-week high at $8.24 amid market optimism

February 13, 2025 | msn.com

ContextLogic Inc. Reports Third-Quarter 2024 Financial Results

November 7, 2024 | globenewswire.com

AstraZeneca pays record 660% premium for gene editing company LogicBio

September 22, 2024 | pharmaphorum.comP

LGCB Linkage Global Inc

September 15, 2024 | seekingalpha.com

ContextLogic Inc. Reports Second-Quarter Financial Results

August 8, 2024 | globenewswire.com

LogicBio Therapeutics, Inc. (LOGC)

May 14, 2024 | finance.yahoo.com

RVVTF Revive Therapeutics Ltd.

March 27, 2024 | seekingalpha.com

LogicBio's IPO: What You Need To Know

September 24, 2023 | finance.yahoo.com

Rare Diseases Market is projected to grow at a CAGR of 12.27% by 2033: Visiongain Reports Ltd

March 31, 2023 | uk.finance.yahoo.com

Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeutics

November 16, 2022 | finance.yahoo.com

LogicBio Therapeutics, Inc.: LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

November 14, 2022 | finanznachrichten.de

LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

November 14, 2022 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
Astera Labs: AI Infrastructure Play With Significant Growth Ahead
By Nathan Reiff | June 26, 2025
View Astera Labs: AI Infrastructure Play With Significant Growth Ahead

LOGC, CASI, ADMA, BCLI, and LJPC Company Descriptions

ADMA Biologics NASDAQ:ADMA

$18.30 +0.16 (+0.85%)

Closing price 07/3/2025 03:54 PM Eastern

Extended Trading

$18.27 -0.03 (-0.14%)

As of 07/3/2025 04:53 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Brainstorm Cell Therapeutics NASDAQ:BCLI

$1.14 -0.03 (-2.56%)

Closing price 07/3/2025 03:55 PM Eastern

Extended Trading

$1.15 +0.01 (+1.23%)

As of 07/3/2025 04:50 PM Eastern

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

CASI Pharmaceuticals NASDAQ:CASI

$1.33 0.00 (-0.02%)

Closing price 07/3/2025 03:17 PM Eastern

Extended Trading

$1.33 0.00 (0.00%)

As of 07/3/2025 04:11 PM Eastern

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

La Jolla Pharmaceutical NASDAQ:LJPC

La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts.

LogicBio Therapeutics NASDAQ:LOGC

LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time